Drugs / BVAC-E6E7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06797986 | Feb 2026 → Mar 2027 expected | human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma | Cellid Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVAC-E6E7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06797986 ↗ |
| Modality | Vaccine | “BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.” NCT06797986 ↗ |
| Route | Intravenous | “6 times by IV injection” NCT06797986 ↗ |